**Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum]**


On page 418, note that under Search strategy, Merck-Shire-Dome should have been listed as Merck, Sharp, and Dohme.

On page 421, Figure 2, the relative risk for golimumab versus placebo for the PsARC response was incorrectly listed as

2.45, and should be 3.45. The mean difference for etanercept versus placebo for the PASI response was incorrectly listed as 2.13, and should be 3.13. The x-axis of the PASI forest plot was incorrectly labeled with mean difference values of 1, 2, 3 and 4. The correct values are 3, 6, 9 and 12.

On page 421, Figure 2, the relative risk for golimumab versus placebo for the PsARC response was incorrectly listed as

- **PsARC**
  - Adalimumab: 2.39 (1.84, 3.12)
  - Etanercept: 3.19 (2.31, 4.42)
  - Infliximab: 2.64 (1.66, 4.21)
  - Golimumab: 3.45 (2.39, 4.99)

- **HAQ (PsARC responders)**
  - Mean difference (95% confidence intervals)
    - Adalimumab: 2.00 (0.05, 0.35)
    - Etanercept: 0.43 (0.23, 0.63)
    - Infliximab: 0.41 (0.23, 0.58)
    - Golimumab: 0.22 (0.01, 0.45)

- **PASI**
  - Mean difference (95% confidence intervals)
    - Adalimumab: 4.11 (2.42, 5.80)
    - Etanercept: 3.13 (1.03, 5.23)
    - Infliximab: 6.44 (1.75, 11.1)
    - Golimumab: 4.90 (3.06, 6.72)

- **HAQ (PsARC non-responders)**
  - Mean difference (95% confidence intervals)
    - Adalimumab: 0.09 (0.03, 0.19)
    - Etanercept: 0.23 (0.09, 0.38)
    - Infliximab: 0.19 (0.08, 0.31)
    - Golimumab: 0.16 (0.03, 0.30)

**Figure 2** Forest plots of direct estimates for anti-TNFs versus placebo comparisons.

Abbreviations: anti-TNF, anti-tumor necrosis factor; HAQ, Health Assessment Questionnaire; PASI, Psoriasis Area and Severity Index; PsARC, Psoriatic Arthritis Response Criteria.